To view a list of recent publications, please click the physician's name. The resources listed are intended for the education of other medical professionals interested in or practicing heart transplantation.
- Randall Starling, MD
Medical Director, Heart Transplant Program and Kaufman Center for Heart Failure
Head, Section of Heart Failure and Cardiac Transplant Medicine
Vice Chairman, Department of Cardiovascular Diseases
- Eugene Blackstone, MD
- Corinne Bott-Silverman, MD
- Gerard J. Boyle, MD
Chairman, Pediatric Cardiology
Head, Section of Pediatric Heart Transplantation and Congestive Heart Failure
- Brian Duncan, MD
- Gonzalo V. Gonzalez-Stawinski, MD
- Mazen A. Hanna, MD
- Robert Hobbs, MD
- Eileen Hsich, MD
- Karen James, MD
- Tomislav Mihaljevic, MD
- Gustavo Rincon, MD
- Rene Rodriguez, MD
Head, Section of Autopsy Pathology, Department of Anatomic Pathology
- W.H. Wilson Tang, MD
- David Taylor, MD
- James Young, MD
Chairman, Division of Medicine
Books/ Book Chapters
Dec GW, Narula J, Young JB (consulting eds). Heart Failure Clinics: Myocarditis. Philadelphia: Elsevier/Saunders; 2005:vol 1(3).
Francis GS, Tang WH. Evolution of disease progression in heart failure. In: Starling RC, O’Neill J, eds. Chapter 13, Heart Failure. American College of Cardiology Self-Assessment Program (ACCSAP) Version 6; American College of Cardiology; 2005:p. 20-28.
Francis GS, Tang WH, Adams K. Pathophysiology of the spectrum of acute heart failure: de-novo heart failure, decompensated heart failure, and advanced refractory heart failure. In: O’Connor CM, Gattis WA, Gheorghiade M, Adams KF, eds. Managing Acute Decompensated Heart Failure: A Clinician’s Guide for Diagnosis and Treatment; 2005:87-93.
Hajjar RJ, del Monte F, Narula J, Young JB (consulting eds). Heart Failure Clinics: Pathogenesis of Heart Failure. Philadelphia: Elsevier/Saunders; 2005:vol 1 (2).
Hobbs RE. Novel drug therapies for heart failure. J Heart Disease. 2005;4 (1):120.
Hobbs RE (ed.). Heart Failure 2005. Norwalk, Conn.: Belvoir Media Group; 2005.
Hobbs RE. Heart Failure Therapeutics. In: ACC-SAP 6, American College of Cardiology. Bethesda, Md.; 2005:13: pp 47-55.
Hobbs RE. Heart Failure. In: Stoller, Mandell, Michota, Eds . The Cleveland Clinic Intensive
Review of Internal Medicine, 4 th Edition . Philadelphia , PA: Lippincott Williams & Wilkins; 2005:pp 862-870.
Hobbs RE. Novel Drug Therapies for Heart Failure. In: Kimchi A, Ed. Proceedings of the 12 th World Congress on Heart Disease–New Trends in Research, Diagnosis and Treatment. Bologna, Italy: Medimond Medical Publications; 2005.
Mills RM, Hobbs RE, et al. Nesiritide-Supported Volume Loading in the Prevention of Contrast-Induced Nephropathy. In: Kimchi A, Ed. Proceedings of the 12 th World Congress on Heart Disease–New Trends in Research, Diagnosis and Treatment. Bologna, Italy: Medimond Medical Publications; 2005.
Narula J, Young JB (consulting eds). Heart Failure Clinics: Neurohumoral Modulators in Heart Failure. Philadelphia: Elsevier/Saunders; 2005;vol 1(1).
Smedira NG, Hoercher KJ, Starling RC. Surgical approaches for heart failure. In: Topol EJ, ed. Textbook of Cardiovascular Medicine 3 rd ed. Lippincott-Williams and Wilkins; 2006.
Tang WH, Stewart W. Sinus of valsalva aneurysm. Available at: www.emedicine.com/. Revised 2005.
Tang WH, Young JB. Myocarditis. Available at www.emedicine.com/. Revised 2005.
Tang WH, Francis GS. B-type natriuretic peptides in acute coronary syndromes. In Topol EJ, ed. Acute Coronary Syndromes III, Chapter 14. New York NY: Marcel Dekker, Inc.; 2005;Page 309-323.
Yamani MH. Basic mechanisms and the pathophysiology of heart failure. In: Lewis RP, ed. ACCSAP VI. Bethesda, Md.: American College of Cardiology Chapter 13 Syllabus; 2005:p. 13.4-13.8.
Young JB. Cell replacement strategies for heart failure. In: Pina I, Goldstein S, Dunlap ME (eds.). The Year in Heart Failure (Vol. 1). Clinical Publishing, Oxford; 2005;chapter 6, pp. 89-99.
Young JB. Pathophysiology of patients with congestive heart failure. In: Savage RM, Aronson S (eds.). Thomas JD, Smedira NG, Shernan SK, Shanewise JK, Wallace L (assoc. eds.). Comprehensive textbook of intraoperative transesophageal echocardiography. Philadelphia: Lippincott, Williams & Wilkins; 2005;chapter 32, pp. 585-591.
Abstracts
Abraham WT, Albert NM, Gattis Stough WE, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB, Fonarow GC. Predictors of In-Hospital Mortality in Patients Hospitalized with Heart Failure: An Analysis of 48,612 Hospitalizations from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Circulation Journal of the Amer Heart Assoc. 2005;vol 112, (17).
Angheloiu GO, Yamani MH, Starling RC, Young JB. Elevated troponin T is associated with increased left ventricular end-diastolic pressure and electrocardiographic left ventricular hypertrophy in congestive heart failure patients with no coronary artery disease. J Am Coll Cardiol. 2005;45 (3): 145A. Presented at ACC, Orlando, FL, March 2005.
Borowski AG, Tang WH, Junor C, Tong W, Martin MG, Kassimatis K, Agler D, Troughton RW, Grimm R, Klein AL. Echocardiographic Criteria for Left Ventricular Dyssynchrony in Patients with Chronic Heart Failure and Narrow QRS Duration: An ADEPT Ancillary Study. Circulation. 2005;112 (17 Suppl): II-755-6. Oral presentation at the American Heart Association Scientific Sessions [Abstract 3522], Dallas TX, 2005.
Butler J, Young JB, Abraham WT, Bourge RC, Adams KF Jr., Hasan MA, Heroux A, Russell SD, Francis GS, Clare R, O’Connor CM. Beta-blocker use and associated outcomes among hospitalized heart failure patients. J Am Coll Card. 2005;45(3A):154A:1103-176.
Chen SYL, Laffey C, Tang WH. Under-Recognition of Diastolic Dysfunction and Left Ventricular Hypertrophy as Cardiac Etiologies of Heart Failure Symptoms in the Primary Care Setting. J Card Fail. 2005;11(6 Suppl): S181. Poster presentation at the 9 th Annual Scientific Meeting of the Heart Failure Society of America [Abstract 341], Boca Raton FL, 2005.
Edwards LB, Taylor DO. Does the choice of immunosuppressive agent impact the development of renal insufficiency following heart transplantation? Am J Transplant. 2005;5 (suppl 11): 249.
J Am Coll Card. 2005;45(3A):339A:1115-190.
Fonarow G, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, O’Connor CM, She L, Yancy CW, Young JB. Can gender-related disparities in the use of evidence-based therapies for heart failure be reduced? A report from The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Card. 2005;45(3A):340A:1115-191.
Fonarow G, Abraham WT, Albert NM, Gattis W, Gheorghiade M, Greenberg B, O’Connor CM, She L, Yancy CW, Young JB. Impact of evidence-based heart failure therapy use at hospital discharge on treatment rates during follow-up: A report from The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Card. 2005;45(3A):345A:844-4.
Fonarow G, Abraham W, Albert N, Gheorghiade M, Greenberg B, O’Connor C, Stough W, Yancy C, Young J, She L. Should beta blocker use at the time of hospital discharge be included as a heart failure performance measure? A report from OPTIMIZE-HF. J Card Fail. 2005;11(6 Suppl):S182:344.
Gheorghiade M, Stough WG, O’Connor CM, Abraham WT, Greenberg BH, Young JB, Albert NM, Yancy CW, She L, Fonarow GC. Serum sodium concentration and mortality in patients admitted with heart failure: an analysis of OPTIMIZE-HF. J Card Fail. 2005;11(6 Suppl):S183:348.
Gheorghiade M, Klein L, Abraham WT, Albert NM, Greenberg BH, O’Connor CM, She L, Stough W, Yancy CW, Young JB, Fonarow GC. The Relation Between Admission Systolic Blood Pressure and Outcomes in Hospitalized Patients with Heart Failure with Reduced or Preserved Systolic Function: An OPTIMIZE-HF Analysis. Circulation Journal of the Amer Heart Assoc. 2005;vol 112, (17).
Gheorghiade M, Klein L, Abraham WT, Albert NM, Greenberg BH, O’Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC. The relation between admission systolic blood pressure and outcomes in hospitalized patients with heart failure: an OPTIMIZE-HF analysis. J Card Fail. 2005;11(6 Suppl):S196:401.
Gonzalez-Stawinski G, Smedira N, Chiu J, Atik F, Chang A, Navia J, Banbury M, Young JB, Taylor DO, Hobbs R, Yamani MH, Starling RC, Hoercher K, Cook DJ. The Association Between Anti-Donor HLA Class I Antibodies and Outcomes in Patients with Cardiac Humoral Rejection. Am J of Transplantation. 2005;Supplement 11:Vol 5 pg. 168. Presented at the Am. Society of Transplantation, May 2005, Seattle, WA.
Gonzalez-Stawinski G, Cook DJ, Chiu J, Banbury M, Navia J, Hoercher K, Yamani MH, Hobbs R, Taylor DO, Young JB, Starling RC. Incidence and Impact on Outcomes of Cardiac Allograft Humoral Rejection After Heart Transplantation. Am J of Transplantation. 2005;Supplement 11: Vol 5 pg. 171. Presented at the Am. Society of Transplantation, May 2005, Seattle, WA.
Gonzales-Stawinski G, Cook DJ, Chang A, Banbury M, Navia J, Hoercher K, Taylor DO, Yamani MH, Lober C, Young JB, Hobbs R, Starling RC, Smedira N. Disparities in Short-term Outcomes Between Bridged to Heart Transplant Recipients and Non-Bridged Recipients. Am J of Transplantation. 2005;Supplement 11: Vol 5 pg. 406. Presented at the Am. Society of Transplantation, May 2005, Seattle, WA.
Grady KL, Rybarczyk B, Naftel DC, Kirklin JK, White-Williams C, Kobashigawa J, Chait J, Young JB, Pelegrin D, Czerr J, Higgins R, McLeod M, Rissinger J, Heroux A. Predictors of negative affect at 5-6 years after heart transplantation. J Heart and Lung Transplantation. 2005;24(2S): S45:11.
Grady KL, Rybarczyk B, Naftel DC, Kobashigawa J, Chait J, Young JB, Pelegrin D, Czerr J, Kirklin JK, White-Williams C, Higgins R, McLeod M, Heroux A. Patterns and Predictors of Emotional Status at 5-10 Years after Heart Transplantation. Circulation Journal of the Amer Heart Assoc. 2005; vol 112, (17).
Greenberg BH, Abraham WT, Albert NM, Gattis Stough WA, Gheorghiade M, O’Connor CM, She L, Yancy CY, Young JB, Fonarow GC. Influence of Diabetes Mellitus on Characteristics and Outcomes in Patients Hospitalized with Heart Failure: A Report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Circulation Journal of the Amer Heart Assoc 2005; vol 112, (17).
Greenberg B, Stough W, Albert NM, Young J, She L, Fonarow G. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from OPTIMIZE-HF. J Card Fail. 2005;11(6 Suppl):S193:386.
Hoercher KJ, Singh G, Alster JM, Blackstone EH, Nowicki ER, Smedira NG. Outcomes of patients removed from a cardiac transplant waiting list. J Heart Lung Transplant. 2006:Feb.
James KB, Troughton RW, Feldschuh J, Soltis D, Thomas D, Fouad-Tarari F. Blood Volume and Brain Natiuretic Peptide in Congestive Heart Failure: A Pilot Study. Am Heart J. 2005;150(5): 984. e 1-984.e6.
James KB, Militello M, Gus B, Wilkoff BL. A Series of Heart Failure Patients Undergoing Resynchronization While on Inotrope Therapy Around the Timing of Pacemaker Implantation. Texas Heart J. Accepted November 2005.
Mezu UL, Philip K, Starling RC, Taylor DO, Francis GS, Tang WH. The impact of baseline glomerular filtration rate on the incidence of worsening renal failure in patients admitted for decompensated heart failure. J Am Coll Cardiol. 2005;45(3 Suppl A): 170A. Poster presentation at the American College of Cardiology Scientific Sessions[Abstract #1133-178], Orlando, 2005.
Am J of Cardiovasc Drugs. Accepted November 2005.
Oliveira GH, Wallace CK, Young JB, Koerner MM, Thohan V, Torre-Amione G. Tumor necrosis factor-a (TNF-a) blockade with etanercept decreases collagen deposition in cardiac allografts. J Card Fail. 2005;11(6 Suppl):S89:003.
Oliveira GH, Wallace CK, Young JB, Thohan V, Koerner MM, Torre-Amione G. Increased collagen deposition and not cardiomyocyte enlargement is responsible for cardiac allograft hypertrophy. J Card Fail. 2005;11(6 Suppl):S132:155.
Sallach JA, Tang WH, Porter T, Borowski AG, Lalude O, Martin MG, Troughton RW, Bhavnani S, Klein AL. Right atrial volume is a marker of right ventricular systolic dysfunction: An ADEPT Trial Sub-study. Circulation. 2005; 112 (17 Suppl): II-342-3. Poster presentation at the American Heart Association Scientific Sessions [Abstract 1704], Dallas TX, 2005.
Sallach JA, Tang WH, Borowski A, Martin MG, Troughton RW, Klein AL. Prognostic significance of right atrial volume in patients with significant left ventricular dysfunction. J Am Coll Cardiol 2005; 45(3 Suppl A): 279A. Poster presentation at the American College of Cardiology Scientific Sessions[Abstract # 1109-89], Orlando, 2005.
Shah T, Yamani MH, Mc Neill A, Avery R, Mawhorter S, Saber S, Cook DJ, Buda T, Yeager M, Hobbs R, Taylor DO, Young JB, Smedira N, Starling RC. The impact of hypogammaglobulinemia on infections in patients with ventricular assist devices. J Am Coll Cardiol. 2005;45(3):11A. Presented at ACC, Orlando, FL, March 2005.
Shah T, Yamani MH, Mc Neill A, Avery R, Mawhorter S, Saber S, Cook DJ, Buda T, Yeager M, Hobbs R, Taylor DO, Young JB, Smedira N, Starling RC. The impact of hypogammaglobulinemia on infections in patients with ventricular assist devices. J Heart Lung Transplant. 2005;24(2S):S101. Presented at ISHLT, Philadelphia, PA, April 2005.
Smith AL, Abraham WT, Young JB, Wheelan KR, Witte LJ, Harsch MR, Storm CM. CRT therapy in patients with a history of atrial fibrillation. J Card Fail. 2005;11(6 Suppl):S153:237.
Sweet WE, Uhrich MG, Banbury M, Navia J, Young JB, Starling RC, Smedira NG, Moravec CS. Beta 2 Adrenergic Receptors Play a Greater Role in the Failing Human Heart Following LVAD Support. Circulation Journal of the Amer Heart Assoc, 2005;vol 112, (17).
Tang WH, Borowski AG, Tong W, Junor C, Troughton RW, Martin MG, Kassimatis K, Agler D, Jasper S, Whitman C, Morehead A, Starling RC, Grimm R, Klein AL. Limitations of Bundle Branch Block (BBB) to Assess Intra-Ventricular Delay in Patients with Advanced Chronic Heart Failure (CHF): An ADEPT Ancillary Study. Circulation. 2005;112 (17 Suppl): II-756. Oral presentation at the American Heart Association Scientific Sessions [Abstract 3523], Dallas TX, 2005.
Tang WH, Troughton RW, Nash P, Bhavnani S, Francis GS, Starling RC, Richards M, Yandle T, Klein AL. Reduction of natriuretic peptides in obese patients with systolic heart failure is independent of peptide types and echocardiographic indices of myocardial performance. J Am Coll Cardiol. 2005;45(3 Suppl A): 140A. Poster presentation at the American College of Cardiology Scientific Sessions[Abstract # 1048-179], Orlando, FL, 2005.
Tang WH, Pepoy M, Wu AHB, Smith A, Olson B. BNP Levels in Minimally Symptomatic Heart Failure. Poster presentation at the 16th IFCC-FESCC European Congress of Clinical Chemistry and Laboratory Medicine (EuroMed Lab), Glasgow, United Kingdom, 2005.
Tang WH, Troughton RW, Nash P, Bhavnani S, Martin MG, Morehead A, Jasper SE, Starling RC, Thomas JD, Klein AL. Relationship between plasma NT-proBNP levels and echocardiographic diastolic indices in patients with systolic heart failure: ADEPT Neurohormonal Sub-study. Eur J Heart Fail. 2005;7(Suppl 1): 81. Oral presentation at the Heart Failure 2005 (ESC Heart Failure Working Group annual meeting) [Abstract 81], Lisbon, Portugal, 2005.
Tang WH, Jain A, Miller H, Harris CM, Young JB. Glycemic control and treatment patterns of patients with heart failure. Eur Heart J. 2005;26(Abstr Suppl): 441. Oral presentation at the European Society of Cardiology Congress 2005 [Abstract 2776].
Tang WH, Hazen SL, Philip K, Stevenson C, Pepoy M, Neale S, Van Lente F, Francis GS. Comparative sensitivities of plasma B-type natriuretic peptide assays in patients with stable chronic heart failure: implications for screening. Eur Heart J. 2005; 26(Abstr Suppl): 741. Poster presentation at the European Society of Cardiology Congress 2005 [Abstract P4162].
Tang WH, Brennan ML, Philip K, Mann S, Van Lente F, Pepoy M, Hazen SL. Elevated Plasma Myeloperoxidase Levels in Patients with Chronic Systolic Heart Failure. J Card Fail. 2005;11(6 Suppl): S121. Circulation. 2005; 112 (17 Suppl): II-725. Poster presentation at the 9 th Annual Scientific Meeting of the Heart Failure Society of America [Abstract 116], Boca Raton FL, 2005. Poster presentation at the American Heart Association Scientific Sessions [Abstract 3387], Dallas, TX, 2005.
Troughton RW, Tang WH, Tong W, Yandle T, Richards M, Klein AL. Plasma Levels of the Vasodilator Peptide Urocortin-1, But Not the Vasoconstrictor Hormone Urotensin-2 Reflect Symptomatic Status and Severity of Diastolic Dysfunction in Systolic Heart Failure Patients. Circulation. 2005;112 (17 Suppl): II-725. Poster presentation at the American Heart Association Scientific Sessions [Abstract 3389], Dallas, TX, 2005.
Wheelan KR, Young JB, Abraham WT, Johnson WB, Witte LJ, Harsch MR. Left ventricular lead thresholds remain stable 36 months post-implant in patients with heart failure. Heart Rhythm. 2005;2(1S); S169:P2-108.
Whitman C, Jasper SE, Tang WH, Troughton RW, Martin MG, Klein AL. Echocardiographic and Neurohormonal Predictors of Impaired Sub-maximal Exercise Capacity Assessed by Six-Minute Walk Test in Patients with Chronic Systolic Heart Failure: An ADEPT Ancillary Substudy. J Card Fail. 2005;11(6 Suppl): S124. Poster presentation at the 9 th Annual Scientific Meeting of the Heart Failure Society of America [Abstract 127], Boca Raton, FL, 2005.
Yamani MH, Cook DJ, Ratliff NB, Tuszcu EM, Yu Y, Hobbs R, Rincon G, Bott-Silverman C, Young JB, Smedira N, Starling R. Peritransplant ischemic injury triggers mobilization of stem cells to allograft following heart transplantation. J Am Coll Cardiol. 2005;45(3):16A. Presented at ACC, Orlando, FL, March 2005.
Yamani MH, Cook DJ, Thomas D, Hobbs R, Taylor DO, Ratliff NB, Buda T, Young JB, Navia J, Banbury M, Smedira N, Starling RC. The Impact of Anti-Thymocyte Globulin (ATG) on Clinical Outcome Following Heart Transplantation: A Holiday From Steroids. Am J of Transplantation. 2005;Supplement 11: Vol 5 pg. 243. Presented at the A. Society of Transplantation, May 2005, Seattle, WA.
Yamani MH, McNeill A, Cook DJ, Tong L, Zhou L, Pelegrin D, Hobbs R, Rincon G, Bott-Silverman C, Taylor DO, Young JB, Navia J, Banbury M, Smedira N, Starling RC. Long-Term Heart Transplant Survivors: Beyond 10 Years. Am J of Transplantation. 2005; Supplement 11:Vol 5 pg. 170. Presented at the A. Society of Transplantation, May 2005, Seattle, WA.
Yamani MH, Erinc S, McNeill A, Ratliff NB, Zhou L, Sendry D, Cook DJ, Hobbs R, Rincon G, Bott-Silverman C, Young JB, Banbury M, Navia J, Smedira N, Starling RC. The Impact of Donor Gender on Cardiac Peri-Transplant Ischemic Injury and Vasculopathy. Am J of Transplantation. 2005;Supplement 11: Vol 5 pg. 169. Presented at the Am. Society of Transplantation, May 2005, Seattle, WA.
Yamani MH, Avery R, Mawhorter S, McNeill A, Cook DJ, Ratliff NB, Pelegrin D, Colosimo P, Kiefer K, Ludrosky K, Buda T, Hobbs R, Taylor DO, Young JB, Smedira N, Starling RC. The Impact of Cytogam on Cardiac Transplant Recipients with Moderate Hypogammaglobulinemia: A Randomized Single CenterStudy. Am J of Transplantation. 2005;Supplement 11: Vol 5 pg. 165. Presented at the Am. Society of Transplantation, May 2005, Seattle, WA.
Yamani MH, Cook DJ, Ratliff NB, Tuszcu EM, Yu Y, Hobbs R, Rincon G, Bott-Silverman C, Young JB, Smedira N, Starling R. Peritransplant ischemic injury triggers mobilization of stem cells to allograft following heart transplantation. J Card Failure. 2005;11(6):S130. Presented at Heart Failure Society of America. Boca Raton, FL, September 2005.
Yamani MH, Rodriguez RE, Cook DJ, McNeill A, Yu Y, Taylor DO, Hobbs R, Zhou L, Tuzcu EM, Young JB, Smedira N, Starling RC. Recurrent cardiac allograft rejection is associated with increased myocardial expression of angiotensin II receptor subtype-1. Circulation. 2005;112(17):II-544. Presented at the AHA scientific sessions. Dallas, TX, Nov. 2005.
Yamani MH, Rodriguez RE, Cook DJ, Wholgemuth J, McNeill A, Zhou L, Taylor DO, Hobbs R, Young JB, Smedira N, Starling RC. Transplant vasculopathy is associated with increased AlloMap gene expression score. Circulation. 2005;112(17):II-457. Presented at the AHA scientific sessions. Dallas, TX, Nov. 2005.
Yancy CW, Abraham WT, Albert NM, Gattis Stough WA, Gheorghiade M, Greenberg BH, O’Connor CM, Young JB, Fonarow GC. Defining the Natural History and Improving Quality of Care for African Americans Hospitalized with Heart Failure: A Report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Circulation Journal of the Amer Heart Assoc. 2005;vol 112, (17).
Young JB, Rogers JG, Portner PM, Oyer PE, Edwards BS, Davis SF, Icenogle TB, Johnson FL, Kormos RL, Lansman SL, Restaino SW. Bridgeto eligibility: LVAS support in patients with relative contraindications to transplantation. J Heart and Lung Transplantation. 2005; 24(2S): S75:101.
Young JB, Harsch MR, Witte LJ. Cardiac resynchronization therapy devices in a heart failure population 70 years and older. J Card Fail. 2005;11(6 Suppl):S153:234.
Young J, Stough W, Albert NM, She L, Fonarow G. Anemia in a hospitalized heart failure population: characteristics and relationship to outcomes. A report from OPTIMIZE-HF. J Card Fail. 2005;11(6 Suppl):S191:378.
Principal Investigator—Dr. Robert Hobbs. OPT-CHF The oxypurinol therapy for CHF Trial. Protocol 500-02-01, IRB#6820.
Principal Investigator—Dr. Robert Hobbs. CARPERTIDE: A phase 2, dose escalation evaluation of the pharmakinetic and hemodynamic effects of Carpertide in subjects with congestive heart failure. Protocol 03-0-162, IRB#6815.
Principal Investigator—Dr. Eileen Hsich. EVEREST Study: The EVEREST Study is a multicenter study, double-blind, placebo-controlled study to evaluate the long-term efficacy and safety of Tolvaptan, a vasopressin antagonist, in patients hospitalized for congestive heart failure.
Principal Investigator—Dr. Karen James. IRB#7405: Assessing Cardiac Compass Trends Data for the Management of Heart Failure.
Dr. Randall Starling—RAD B253 Study, Novartis Pharmaceutical; Nutley, New Jersey, 1999-current
Dr. Randall Starling—Zenapax Clinical Trial, Roche Pharmaceutical, 1999-current
Dr. Randall Starling—LVAD Working Group Steering Committee, Baylor College of Medicine; Houston, Texas, 2000-Dr.
Randall Starling—Member, Clinical Trial Steering Committee, Acorn Cardiovascular Clinical Trial, 2001-current
Co-Principal Investigator—Dr. Randall Starling. Clinical evaluation of Acorn cardiac support device therapy in patients with dilated cardiomyopathy (ACORN). IRB#3975. The Cleveland Clinic. Jan. 2, 2001-current. $283,750 total.
Principal Investigator—Dr. Randall Starling. Natriuretic gene expression in cardiac allograft rejection. IRB#3270. The Cleveland Clinic. January 2001 – current
Principal Investigator—Dr. Randall Starling A two-year extension to a two-year prospective, multicenter, randomized, double-blind, double-dummy, active controlled, safety and efficacy study of SDZRAD (RAD001) versus azathioprine as a part of a triple immunosuppressive therapy regimen in de novo heart transplant recipients. IRB#4057. The Cleveland Clinic. $60.000 total.
Principal Investigator—Dr. Randall Starling. A two-year randomized, multicenter, double-blind study of the efficacy and safety of SDZ RAD versus azathioprine as part of an immunosuppressive therapy regimen in de novo heart transplant recipients. SDZ RADB253. IRB#4057. The Cleveland Clinic.
Principal Investigator—Dr. Wilson Tang. IRB#4918: Registry: prevalence and clinical characteristics of co-morbidities in patients with chronic heart failure in different clinical practice settings.
Principal Investigator—Dr. Wilson Tang. IRB#7187: Metabolic abnormalities in patients with chronic heart failure.
Principal Investigator—Dr. Wilson Tang. IRB#7188: Abnormalities of glucose and lipid metabolism in patients undergoing cardiac catheterization.
Principal Investigator—Dr. Wilson Tang. IRB#7212: Long-term metabolic derangements following cardiac transplantation.
Principal Investigator—Dr. Wilson Tang. IRB#7321: Insulin resistance and oxidative stress in reverse remodeling following beta-blocker therapy in dilated cardiomyopathy (BIRC).
Principal Investigator—Dr. Wilson Tang. IRB#7823: Intrathoracic impedance measurements using InSync Sentry devices in patients with heart failure.
Principal Investigator—Dr. Wilson Tang. IRB#8120: Improving endothelial dysfunction and nitric oxide-derived oxidative stress in African American and Caucasian patients with chronic heart failure using hydralazine and isosorbide dinitrate (REDUCE).
Principal Investigator—Dr. Wilson Tang. IRB#8406: Improving nitric oxide-derived oxidants using rosiglitazone in non-diabetic dilated cardiomyopathy (NORDIC).
Principal Investigator—Dr. Wilson Tang. IRB#8409: Improving nitric oxide-derived oxidants using darbepoetin alfa in patients with chronic systolic heart failure and anemia: a mechanistic study.
Principal Investigator—Dr. Wilson Tang. IRB#8517: Hemodynamic assessment of heart failure and pulmonary hypertension in the contemporary era.
Principal Investigator—Dr. Wilson Tang. IRB#8617: Long-term cardiac remodeling in patients with heart failure.
Principal Investigator—Dr. Wilson Tang. IRB#8638: Preoperative percutaneous coronary intervention in patients undergoing non-cardiac surgery.
Principal Investigator—Dr. Wilson Tang. IRB#7345: A randomized, double-blind, placebo-controlled dose-ranging study of the effects of KW-3902, both as monotherapy and in combination with furosemide on diuresis and renal function in patients with congestive heart failure and renal impairment treated with oral loop diuretics who required hospitalization and fluid overload (CKI-201), NovaCardia Pharmaceuticals (completed).
Principal Investigator—Dr. Wilson Tang. IRB#7702: A multi-center, randomized, double-blind, placebo-controlled study of DITPA in patients with NYHA class III and IV congestive heart failure who have low serum T3 levels (DIPTA 803), Titan Pharmaceuticals.
Principal Investigator—Dr. Wilson Tang. IRB#7738: A Phase 2, randomized, double-blind, parallel group, placebo-controlled, multicenter study to examine the effects of AC2592 administered by continuous subcutaneous infusion in subjects with advanced chronic congestive heart failure (AC 2592-101), Amylin Pharmaceuticals.
Principal Investigator—Dr. David Taylor. Transplant-eligible patient management for congestive heart failure (TMAC) with continuous infusion of nesiritide or placebo, sponsored by Scios, Johnson and Johnson.
Principal Investigator—Dr. David Taylor. Extracorporal ultrafiltration vs. usual and customary care for patients with severe heart failure, sponsored by NxStage Inc.
Principal Investigator—Dr. Mohamad Yamani. IRB#4260: The role of angiotensin II receptors in recurrent acute cardiac allograft rejection, sponsored by Kaufman Center for Heart Failure.
Principal Investigator—Dr. Mohamad Yamani. IRB#4260: The role of ischemic injury in triggering mobilization of stem cells to the myocardium in heart transplant patients, sponsored by Kaufman Center for Heart Failure.
Principal Investigator—Dr. Mohamad Yamani. IRB#4091: HOLIDAY FROM STEROIDS: The Impact of Anti-Thymocyte Globulin (ATG) on Clinical Outcome Following Heart Transplantation, sponsored by Genzyme/Fujisawa.
Principal Investigator—Dr. James Young. IRB#3211: EFECT: Eternacept/TNFC:FC. A phase II, double-blind, placebo-controlled study of the effect of anti-TNF therapy in cardiac allograft function. Immunex, Cleveland Clinic (2001-present).
Principal Investigator—Dr. James Young. IRB#4797: REVIVE: Phase III randomized multicenter evaluation of intravenous levosimendan efficacy versus placebo in the short -term treatment of decompensated chronic heart failure. Orion/Abbott, Cleveland Clinic (2002-present).
Principal Investigator—Dr. James Young. IRB #5614: CHART: Registry for heart failure and arrhythmia research. USC/Guidant Foundation, Cleveland Clinic (2002-present).
Principal Investigator—Dr. James Young. IRB #6002. OPTIMIZE-HF: Organized program to initiate life-saving treatment in hospitalized patients with heart failure: an internet-based registry and process of care improvement program for heart failure patients. GlaxoSmithKline, Cleveland Clinic (2002-present).
Study Chairman—Dr. James Young. INTERMACS (Interagency Registry of Mechanically Assisted Circulatory Support). National Heart, Lung and Blood Institute (NHLBI) Contract #HHSN 2682005A8198C.
International Co-Principal Investigator—Dr. James Young. ACT-HF (Anemia Correction Trial–Heart Failure). Amgen Protocol: 2A050222.
International Principal Investigator—Dr. James Young. ACCLAIM: Multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the effects of immune modulation therapy (IMT) on mortality and morbidity in patients with chronic heart failure. Vasogen.
United States Co-Principal Investigator—Dr. James Young. ONTARGET/TRANSCEND: Ongoing Telmisartan above and in combination with ramipril global endpoint/Telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease. Boehringer Ingelheim.
Member—Dr. James Young. Muraglitazar Clinical Trials Program Data Monitoring and Safety Board. Bristol-Myers Squibb (2004-present).